Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

https://www.news-medical.net/news/20251209/Enterprise-Therapeutics-publishes-results-of-Phase-1-study-of-ETD001-a-novel-inhaled-ENaC-blocker-for-treatment-of-Cystic-Fibrosis-in-The-Journal-of-Cystic-Fibrosis.aspx